ENTA Live signals | Maximize Profits with Getagraph.com

BUY 151266 min ago

@ $13.07

Issued: 14 Feb 2024 @ 15:52

Return: -8.92%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 4.73 %

Live Chart Being Loaded With Signals

Commentary (29 May 2024 @ 16:00):

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases...

Stats
Today's Volume	78 952.00
Average Volume	189 893
Market Cap	252.03M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-1.490 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.920
ATR14	$0.0230 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	Kowalsky Matthew Paul	Buy	150 000	Stock Option (right to buy)
2024-04-29	Kowalsky Matthew Paul	Buy	0
2024-03-06	Vance Terry	Buy	15 700	Stock Option (right to buy)
2024-03-06	Russell Lesley	Buy	15 700	Stock Option (right to buy)
2024-03-06	Peterson Kristine	Buy	15 700	Stock Option (right to buy)

INSIDER POWER
75.69
Last 99 transactions
Buy: 1 413 491 \| Sell: 286 116

Volume Correlation

Long: 0.28 (neutral)

Short: 0.06 (neutral)

Signal:(61.622) Neutral

Enanta Pharmaceuticals Correlation

10 Most Positive Correlations
NICE	0.91
FTCS	0.881
VSMV	0.877
BLDR	0.868
RTH	0.867
TARA	0.865
CRNT	0.864
FAST	0.858
SIGIP	0.857
PCAR	0.857

10 Most Negative Correlations
BLKB	-0.811
IRDM	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enanta Pharmaceuticals Correlation - Currency/Commodity

0.39
( neutral )

0.54
( weak )

0.00
( neutral )

0.34
( neutral )

0.61
( weak )

-0.25
( neutral )

Enanta Pharmaceuticals Financials

Annual	2023
Revenue:	$79.20M
Gross Profit:	$76.83M (97.01 %)
EPS:	$-6.38

FY	2023
Revenue:	$79.20M
Gross Profit:	$76.83M (97.01 %)
EPS:	$-6.38

FY	2022
Revenue:	$86.16M
Gross Profit:	$83.19M (96.55 %)
EPS:	$-5.91

FY	2021
Revenue:	$97.07M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.92

Financial Reports:

No articles found.

Enanta Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.